Peer-reviewed findings with our proprietary technology: Evoked Potential Tomography (EPT). EPT, which underpins Ceregram, has been evidenced in clinical research publications for Alzheimer’s, Schizophrenia, and other indications. EPT has held several names, including CASBA and JH-FLKR.
Poster: American Academy of Neurology 2025 (click to enlarge)
A pre-print is also available here
Prior Publications
Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment
Amyloid deposition is a key predictor of Alzheimer’s disease (AD) and related neurodegenerative disorders. Changes in the retina’s ganglion cell layer are linked to AD. The study examines EEG visual event-related potentials (vERP) as a measure of dysfunction in visual systems tied to the ganglion cell layer. Specifically, it assesses how amyloid deposition affects vERP in aging and mild cognitive impairment (MCI) populations. The research aims to clarify the connection between amyloid buildup and vERP changes, potentially aiding early AD detection and progression monitoring.
Differential patterns of visual sensory alteration underlying face emotion recognition impairment and motion perception deficits in schizophrenia and autism spectrum disorders
Schizophrenia (SZ) and autism spectrum disorder (ASD) share face-emotion recognition and motion processing deficits. SZ shows reduced brain activation and lower EEG power in motion-sensitivity regions, while ASD features dorsal stream hyperactivation and increased theta power. Both groups exhibit abnormal alpha-band modulation in the pulvinar, predicting clinical symptoms. These distinct profiles suggest potential treatments for regulating visual processing in SZ and ASD.
Roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology
Developing treatments for psychiatric disorders relies on physiological measures that bridge the gap between animal models and human studies. Traditional EEG event-related potentials (ERPs) vary significantly across species. Neuro-oscillatory responses, analyzed in the time-frequency domain, offer more consistent comparisons and insights into local circuit mechanisms. This paper outlines a roadmap for using neuro-oscillatory responses as translational biomarkers in the development of neuropsychiatric treatments, improving translation from animal models to clinical studies.
Impaired motion processing in schizophrenia and the attenuated psychosis syndrome: etiological and clinical implications
This study explores motion perception deficits in schizophrenia and clinical high-risk (attenuated psychosis) patients, revealing impairments linked to face-emotion recognition and cognitive function. Unlike motion, sensory responses are preserved in attenuated psychosis. In schizophrenia, motion deficits are associated with impaired motion-sensitive visual cortex activity. These findings use EEG to underscore sensory-level visual dysfunction’s role in schizophrenia, potentially preceding illness onset and affecting clinical high-risk patients.